Outlook Therapeutics News - OTLK

Company Name	Stock Ticker Symbol	Market	Type
Outlook Therapeutics Inc	OTLK	NASDAQ	Common Stock

	Price Change	Change Percent	Stock Price	Last Traded
	-0.12	-1.45%	8.17	16:02:00

Open Price	Low Price	High Price	Close Price	Prev Close
8.28	8.00	8.63	8.17	8.29

more quote information »

Recent News

Date	Time	Source	Heading
4/15/2024	16:15	GLOBE	Outlook Therapeutics® Announces Closing of Private Placement..
3/22/2024	07:35	GLOBE	Outlook Therapeutics® Receives European Union Positive CHMP..
3/18/2024	17:10	GLOBE	Outlook Therapeutics® Announces Closing of Private Placement..
3/12/2024	08:05	GLOBE	Outlook Therapeutics® Announces Effective Date for 1-for-20..
3/11/2024	16:43	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/08/2024	16:30	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/08/2024	16:18	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/08/2024	16:11	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/08/2024	16:08	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
3/07/2024	16:16	EDGAR2	Form 8-K - Current report
2/14/2024	17:10	EDGAR2	Form 10-Q - Quarterly report [Sections 13 or 15(d)]
2/14/2024	16:40	EDGAR2	Form 8-K - Current report
2/14/2024	08:05	GLOBE	Outlook Therapeutics® Reports Financial Results for First..
2/08/2024	07:00	EDGAR2	Form ARS - Annual Report to Security Holders
2/08/2024	06:59	EDGAR2	Form DEF 14A - Other definitive proxy statements
1/31/2024	16:01	EDGAR2	Form SC 13D/A - General statement of acquisition of..
1/31/2024	08:05	GLOBE	Outlook Therapeutics® Doses First Subject in NORSE EIGHT
1/29/2024	17:00	EDGAR2	Form PRE 14A - Other preliminary proxy statements
1/24/2024	17:00	EDGAR2	Form 10-K/A - Annual report [Section 13 and 15(d), not S-K..
1/24/2024	06:02	EDGAR2	Form 8-K - Current report
1/23/2024	08:00	GLOBE	Outlook Therapeutics® Receives FDA Agreement Under Special..
12/22/2023	17:00	EDGAR2	Form 10-K - Annual report [Section 13 and 15(d), not S-K..
12/22/2023	16:15	EDGAR2	Form 8-K - Current report
12/22/2023	08:05	GLOBE	Outlook Therapeutics® Reports Financial Results for Fiscal..
12/19/2023	08:05	GLOBE	Outlook Therapeutics® Submits Special Protocol Assessment..
12/18/2023	05:45	PRNUS	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
12/06/2023	17:00	EDGAR2	Form 8-K - Current report
12/06/2023	08:05	GLOBE	Outlook Therapeutics® Announces Strategic Organizational..
12/04/2023	05:45	PRNUS	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/29/2023	16:01	EDGAR2	Form SC 13D/A - General statement of acquisition of..
11/28/2023	05:45	PRNUS	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/27/2023	08:05	GLOBE	Outlook Therapeutics® Announces Receipt of Type A Meeting..
11/21/2023	05:45	PRNUS	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/14/2023	08:05	GLOBE	Outlook Therapeutics® Adds Global Commercial Expertise with..
11/14/2023	05:45	PRNUS	SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders..
11/02/2023	08:12	EDGAR2	Form 8-K - Current report
11/02/2023	08:05	GLOBE	Outlook Therapeutics® Provides Update on Type A Meetings..
11/01/2023	08:05	GLOBE	Outlook Therapeutics® to Present at Guggenheim’s 5th Annual..
10/20/2023	17:00	EDGAR2	Form 8-K - Current report
10/05/2023	17:15	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/05/2023	17:14	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/05/2023	17:07	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
10/05/2023	17:06	EDGAR2	Form 4 - Statement of changes in beneficial ownership of..
9/29/2023	08:05	GLOBE	Outlook Therapeutics® Requests Type A Meeting With FDA
9/21/2023	08:05	GLOBE	Outlook Therapeutics® to Present at the 2023 Cantor..
9/05/2023	08:05	GLOBE	Outlook Therapeutics® to Present at the H.C. Wainwright 25th..
8/30/2023	06:21	EDGAR2	Form 8-K - Current report
8/30/2023	06:00	GLOBE	Outlook Therapeutics® Provides Regulatory Update on FDA..
8/25/2023	16:31	EDGAR2	Form 424B5 - Prospectus [Rule 424(b)(5)]
8/14/2023	17:19	EDGAR2	Form S-3 - Registration statement under Securities Act of..